

S 977

Transparent Drug Pricing Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Apr 1, 2019

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Apr 1, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/977>

Sponsor

Name: Sen. Scott, Rick [R-FL]

Party: Republican • **State:** FL • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Hawley, Josh [R-MO]	R · MO		Apr 1, 2019

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Apr 1, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 1, 2019)

Transparent Drug Pricing Act of 2019

This bill establishes several requirements relating to the prices of prescription drugs.

For example, state Medicaid drug-use review programs must require pharmacists to disclose an individual's out-of-pocket cost for a prescription drug, and the price without health insurance, at the point-of-sale. Additionally, health insurers must publish the co-payment amount for each covered prescription drug prior to the annual open-enrollment period.

The bill also temporarily prohibits the retail list price of drugs and biologics from exceeding the lowest retail list price among Canada, France, the United Kingdom, Japan, or Germany.

Actions Timeline

- **Apr 1, 2019:** Introduced in Senate
- **Apr 1, 2019:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.